Prabhudas Lilladher's research report on PI Industries
PI Industries reported consolidated revenue from operations of Rs18.7bn, reflecting a 16% YoY and 1% QoQ decline. The CSM segment, which contributes around 75% of total revenue, witnessed 18% YoY and 5% QoQ degrowth, impacted by subdued global agrochemical demand. The segment is expected to recover from Q4FY26 onwards. However, new product launches in this segment delivered robust 38% YoY growth. The domestic agchem branded business also declined 13% YoY, as erratic rainfall disrupted demand. Additionally, the biologicals segment was affected by regulatory challenges, which have now been resolved. The pharma business, still in its ramp-up phase, reported revenue of Rs634mn, up 54% YoY. While the segment remains loss making, management expects breakeven at around Rs5bn in revenue. We expect near-term challenges in the agrochemical space to weigh on overall performance.
Outlook
However, medium-term growth will be supported by new CSM product launches, biologicals recovery, and scale-up in pharma. We estimate consolidated revenue/EBITDA/PAT CAGR of ~5%/7%/6% over FY25–28E. At current levels, the stock trades at 28x Sep’27E EPS. We value the stock at 29x Sep’27E EPS, arriving at a target price of Rs3,666, and maintain our ‘HOLD’ rating.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!